A sustained-release dexamethasone device implanted during pars plana vitrectomy may be effective in pre-emptively reducing macular edema in patients with various underlying ocular diseases at risk for ...

IRVINE, Calif.--(BUSINESS WIRE)--Allergan, Inc., (NYSE: AGN) announced today that the U.S. Food and Drug Administration (FDA) has approved OZURDEX® (dexamethasone intravitreal implant) 0.7 mg, a ...

To evaluate the morphological and functional changes following intravitreal Ozurdex (dexamethasone implant) injections in patients with macular oedema (MO) secondary to retinal vascular diseases. The ...

Please provide your email address to receive an email when new articles are posted on . Intravitreal steroids have been widely used in the treatment of various ocular pathologies including macular ...

OZURDEX (dexamethasone) intravitreal implant by Allergan Allergan's Ozurdex (dexamethasone intravitreal implant) has been approved by the FDA for the treatment of macular edema following branch ...

A case report of a 13-year-old boy with Rhodopsin-positive, CRB1-negative retinitis pigmentosa presenting with Coat’s-like exudative vitreoretinopathy and treatment-resistant cystoid macular oedema.

Dexamethasone implants appear to be the best treatment for persistent or recurrent macular edema that often occurs in patients with uveitis, findings from a new study show. The 12-week, multicenter, ...

There has been dramatic growth in the number of intravitreal injections performed annually. This paper features expert panel consensus regarding the use of intravitreal injections and serves as an ...

What is behind the bilateral eye pain and failing vision affecting a 96-year-old woman with neovascular age-related macular degeneration (nAMD)? That's what ophthalmologists needed to determine when ...

CHICAGO -- Retinal injections for eye disease had a significant association with increased complications rates after cataract surgery, according to a large retrospective cohort study. Seven different ...